Seeking Stronger Foothold in Clinical Sequencing, Roche Proposes to Acquire Illumina in $5.7B Hostile Takeover | GenomeWeb

By Julia Karow

This article has been updated from a previous version with information from a Roche conference call to discuss the proposed acquisition.

Roche has made a $5.7 billion hostile takeover bid for Illumina to bolster its clinical sequencing capabilities and gain a stronger foothold in the personalized medicine market through close collaboration with its pharmaceutical arm.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.